NurExone Biologic (J90) Ratios
4 Followers
NurExone Biologic Ratios
DE:J90's free cash flow for Q2 2026 was $-990.00K. For the 2026 fiscal year, DE:J90's free cash flow was decreased by $-34.00K and operating cash flow was $-956.00K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.63 | 4.11 | 1.04 | 4.46 | 1.74 |
| Quick Ratio | 2.63 | 4.11 | 1.04 | 4.46 | 1.74 |
| Cash Ratio | 2.16 | 1.76 | 0.28 | 4.08 | 1.37 |
| Solvency Ratio | -4.68 | -7.29 | -1.82 | -11.68 | -0.99 |
| Operating Cash Flow Ratio | -4.56 | -12.28 | -1.54 | -6.38 | -0.75 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -1.17 |
| Net Current Asset Value | $ 1.28M | $ 954.00K | $ 1.00K | $ 1.99M | $ 1.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.01 | 0.01 | 0.02 | 0.37 |
| Debt-to-Equity Ratio | 0.04 | 0.02 | 0.11 | 0.02 | 0.89 |
| Debt-to-Capital Ratio | 0.04 | 0.02 | 0.10 | 0.02 | 0.47 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.48 | 1.39 | 11.48 | 1.33 | 2.41 |
| Debt Service Coverage Ratio | -198.97 | -290.71 | -1201.00 | -246.12 | -1.61 |
| Interest Coverage Ratio | -203.97 | -294.65 | -1219.00 | -230.88 | -131.78 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 1.85 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.64 |
| Net Debt to EBITDA | 0.33 | 0.13 | 0.14 | 0.30 | 0.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 99.98% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.96% | 100.70% | 99.51% | 107.22% | 96.15% |
| Return on Assets (ROA) | -156.36% | -206.60% | -167.70% | -292.38% | -57.64% |
| Return on Equity (ROE) | -231.47% | -286.37% | -1925.40% | -389.74% | -138.89% |
| Return on Capital Employed (ROCE) | -204.36% | -245.18% | -1395.80% | -347.74% | -141.10% |
| Return on Invested Capital (ROIC) | -201.88% | -244.94% | -1306.07% | -343.97% | -75.63% |
| Return on Tangible Assets | -156.36% | -206.60% | -167.70% | -292.38% | -57.64% |
| Earnings Yield | -16.60% | -17.89% | -36.59% | -75.25% | -289.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.06 | -0.07 | -0.07 | -0.10 | -0.74 |
| Free Cash Flow Per Share | -0.06 | -0.08 | -0.07 | -0.10 | -0.74 |
| Dividend Paid and CapEx Coverage Ratio | -82.02 | -7.53 | -24.51 | -74.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -82.02 | -7.53 | -24.51 | -74.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -41.77 | -148.12 | -147.05 | -87.45 | -1.17 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -11.87% | -19.65% | -30.77% | -35.92% | -216.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.02 | -5.59 | -2.73 | -1.31 | -0.34 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 13.94 | 16.00 | 52.63 | 5.18 | 0.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.42 | -5.09 | -3.25 | -2.78 | -0.46 |
| Price-to-Operating Cash Flow Ratio | -8.52 | -5.77 | -3.38 | -2.82 | -0.46 |
| Price-to-Earnings Growth (PEG) Ratio | -1.72 | 1.06 | 0.04 | 0.02 | -0.00 |
| Enterprise Value Multiple | -5.91 | -5.57 | -2.62 | -1.04 | 0.37 |
| Enterprise Value | 36.43M | 27.52M | 9.43M | 8.44M | -619.50K |
| EV to EBITDA | -5.91 | -5.57 | -2.62 | -1.04 | 0.37 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.98 | -4.97 | -3.08 | -2.16 | 0.51 |
| EV to Operating Cash Flow | -8.07 | -5.63 | -3.20 | -2.19 | 0.51 |
| Tangible Book Value Per Share | 0.03 | 0.03 | 0.00 | 0.06 | 0.71 |
| Shareholders’ Equity Per Share | 0.03 | 0.03 | 0.00 | 0.06 | 0.71 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.08 | -0.08 | -0.08 | -0.22 | -0.98 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.96 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.71 | 0.97 | 0.81 | 0.47 | 0.75 |
Currency in USD
